Weight-loss giant Eli Lilly joined Moonwalk Biosciences' latest funding round, which will be used to advance the biotech's adipose tissue–directed siRNA therapy into first-in-human studies for obesity in late 2027. In addition to the US pharma, the financing saw participation from Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures. The oversubscribed $70-million series B was co-led by Alpha Wave Ventures and YK Bioventures. The round comes more than two and a half yea

Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant FCD, a rare and severe form of epilepsy 8 September 2026 — PannTheraPi, a clinical-stage biopharmaceutical company developing innovative treatments for neurological diseases by selectively targeting the pannexin 1 (Panx1) channel, today announces approval by the French National Agency for the Safety of Medicines and Health Products (ANSM) of its Phase 2a clinical trial evaluating

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide. Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release . Menarini will take over regulatory submissions and commercialization in a total of 39 countries, incl

- Oral Presentation in Session VI: Hereditary Angioedema Sept. 4, 2026 -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that updated Phase II data from its ongoing BW-20805 study for hereditary angioedema (HAE) was selected for oral presentation at the Bradykinin Symposium 2026, being held on September 3-4, 2026 in Berlin, Germany. BW-20805 has shown impressive efficacy throughout the Phase II trial and da

Pfizer has found a new home for an early-stage antibody-drug conjugate (ADC) it gained through its $43-billion takeout of Seagen — then subsequently binned — according to a US securities filing from Medicus Pharma on Wednesday. In March, the pharma terminated a Phase I trial of PF-08046031 (SGN-CD228A) in patients with melanoma and other solid tumours, citing "strategic reasons." The melanotransferrin (CD228)–targeting candidate is one of more than a half-dozen Seagen-sourced ADCs that Pfizer h

US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity. The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and Company, Gaingels, Insight Partners, Nvidia, and RA Capital Management. The company plans to use the pr

GSK is spending up to $1.3 billion on a first-of-its-kind cancer therapy slated to enter the clinic this year. In a deal announced Thursday, GSK agreed to pay Hutchmed $110 million up front, and potentially roughly $1.19 billion more in milestone payments and royalties, for a majority of the rights to a treatment known as HMPL-A830. That treatment is what Hutchmed refers to as an “antibody-targeted therapeutic conjugate,” and could potentially address multiple tumor types. Typical antibody-dru

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA) U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development and eligibility for accelerated approval and priority review Phase 3 design fully aligned with FDA; Biologics License Application (BLA) filing anticipated in 2028 OCU410 is designed as a one-time subreti

Signatera demonstrates 100% positive predictive value for treatment response assessment, detects recurrence months earlier than imaging, and supports precise, individualized lymphoma management through serial ctDNA monitoring Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life Sept. 01, 2026 -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biot